References
- SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnn Rheum Dis201069696497520444750
- SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
- SaagKGTengGGPatkarNMAmerican College of RheumatologyAmerican College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Rheum200859676278418512708
- HoekstraMHaagsmaCNeefCProostJKnuifAvan de LaarMBioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritisJ Rheumatol200431464564815088287
- KubischSAWeigandTPlischkeHMenningerHBioverfugbarkeit von Methotrexat (MTX) in unterschiedlichen Applikationsarten [Bioavailability of Methotrexate (MTX) following different routes of application]Akt Rheumatol200429197200 German
- BraunJKästnerPFlaxenbergPMC-MTX.6/RH Study GroupComparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trialArthritis Rheum2008581738118163521
- AuvinetBJarrierILe LevierFPegonYTurcantAAllainPCompared bioavailability of methotrexate administered orally or intramuscularly in rheumatoid arthritisPresse Med2117822 French1535146
- CronsteinBNLow-dose methotrexate: a mainstay in the treatment of rheumatoid arthritisPharmacol Rev200557216317215914465
- HermanRAVeng-PedersenPHoffmanJKoehnkeRFurstDEPharmacokinetics of low-dose methotrexate in rheumatoid arthritis patientsJ Pharm Sci19897821651712715941
- Müller-LadnerURockwitzKBrandt-JürgensJMC-MTX.10/RH Study GroupTolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritisOpen Rheumatol J20104152220461222
- ArnettFCEdworthySMBlochDAThe American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritisArthritis Rheum1988313153243358796
- PrevooMLLvan ‘t HofMAKuperHHvan LeeuwenMAvan de PutteLBvan RielPLModified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis Rheum199538144487818570
- van RielPLSchumacherHRHow does one assess early rheumatoid arthritis in daily clinical practice?Best Pract Res Clin Rheumatol2001151677611358415
- ICH harmonisation for better health [webpage on the Internet]GenevaHarmonised Tripartite Guideline for Good Clinical Practice (E6) Available from: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/good-clinical-practice.htmlAccessed May 30, 2014
- KeiningerDCoteurGAssessment of self-injection experience in patients with rheumatoid arthritis: psychometric validation of the Self-Injection Assessment Questionnaire (SIAQ)Health Qual Life Outcomes20119221232106